Navigation Links
UK Suggestion for Restricted Use of Anti-AMD Drugs Draws Flak

elf was denied Lucentis after being diagnosed with wet AMD last year, said the Nice guidance was "obscene".

Joanna Potts, business unit director of ophthalmology for Novartis, which markets Lucentis in the UK, said: "The clinical and health economic data supports the use of Lucentis in all types of wet AMD and for both the first and second eye affected, yet Nice appear to have ignored this robust body of evidence."

Macugen is manufactured by Pfizer. The company's medical director David Gillen said: "Pfizer is very disappointed with this preliminary decision. Macugen has been shown to maintain vision in patients with all types of wet AMD and has a licence to reflect this."

A spokeswoman for the Department of Health said Primary Care Trusts should not withhold funding for the drugs in light of the draft guidance.

She added: "This is not final guidance to the NHS from Nice but draft recommendations that have been issued for consultation which the Department of Health will be responding to.

"Macugen and Lucentis are licensed drugs and we have made it clear to PCTs that they should not withhold funding for treatments because Nice guidance is not available."

But shadow health minister John Baron said: "This decision is very odd given that Gordon Brown's constituents are going to get Macugen and Lucentis on the NHS, but patients in England are not."


'"/>




Page: 1 2 3

Related medicine news :

1. Suggestions to reduce global heart disease burden
2. HIV Experts Criticize Australian PMs Suggestion for Ban on Entry of HIV-infected
3. HIV Experts Criticize Australian PMs Suggestion for Ban on Entry of HIV-infected
4. Restricted Activity Predicts Disability
5. Increase in HIV Cases Due To Restricted Offering of the Preventive Treatment
6. Junk Food Advertisements To Be Restricted In All Forms of Media
7. Junk Food Promotional Ads To Be Restricted: Blair
8. Restricted Fetal Growth Increases Risk of Irritable Bowel Syndrome
9. Review Urges Restricted Use Of Devices To Keep Heart Patients Alive
10. Pies Restricted To Once A Term For Kiwi School Kids
11. Lean Protein Could Be Key to Obesity Drugs
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...ssibility of adverse effects with the use of the n...s.// A new study that is set to appear in this mo...on has cautioned on the use of the new group of dr...developed for the treatment of osteoporosis. They ...
...y pressure to resolve apparent obstructive sleep a...cording to researchers.// Timothy Morgenthaler, M...in the Sept. 1 issue of Sleep reports that complex...t to lose sleep from a combination of physical and...
...ologists in New Zealand has led the Hawkes Bay dis...logists worldwide; a scheme being tried out for th...og of undiagnosed medical reports. The medical cou...overseas radiologists are not registered under the...
...n E intake by mothers during pregnancy may heighte... Graham Devereux, of the department of environment...Aberdeen, Scotland and his team conducted this stu...gs of an earlier study conducted by the same team....
Other Medicine News:Health News:Estrens For Osteoporosis Might Have Adverse effects 2Health News:Complex Apnea May Explain Sleepless Nights 2Health News:Complex Apnea May Explain Sleepless Nights 3Health News:Complex Apnea May Explain Sleepless Nights 4Health News:Intake of vitamin E during pregnancy influences asthma risk in kids 2
(Date:9/4/2008)...ain on Schedule with Two Abstracts Accepted for ... November 2008, BRIDGEWATER, N.J., Sept. 4 /PRNew...lty pharmaceutical company focused on the treatmen...nnounced the appointment of,Peter L. Garrambone, J...rrambone,s career includes more than 50 pharmaceut...
(Date:9/3/2008)...on Asked. Wrong Children Studied. Wrong,Conclusion...wire/ -- A Centers for Disease,Control and Prevent...link,between the MMR vaccine and autism. The Natio...nothing to dispel the growing public concern over ...stions concerning design,and methodology., For ye...
(Date:9/3/2008)... Rheumatology Research and Education Foundation,s ...nces in Detecting, Treating an... -- For the first time during its,unprecedented in...the,American College of Rheumatology Research and ...acquired from research funded by the Within Our,Re...
(Date:9/3/2008)...ational Vascular Disease Awareness Month, CHARLOT...harmaceuticals,LLC, a clinical-stage drug-developm...tment of unmet medical needs, announced today that...linical trial of its lead drug,candidate trans sod...725881,on the clinicaltrials.gov Website, is inves...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2CDC Misses Target With Flawed MMR/Autism Study 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX 770 15309 1Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX 770 15309 2Cellectricon Launches Worlds First System for High Throughput RNAi Screening 15305 1Cellectricon Launches Worlds First System for High Throughput RNAi Screening 15305 2VA Reaches Out to Women Veterans 15301 1VA Reaches Out to Women Veterans 15301 2VA Reaches Out to Women Veterans 15301 3ThalesNano Announces the Launch of X Cube Flash 28TM 29 its Next Generation High Temperature and Pressure Continuous Process Reactor 15297 1ThalesNano Announces the Launch of X Cube Flash 28TM 29 its Next Generation High Temperature and Pressure Continuous Process Reactor 15297 2
... subset analyses of progression-free survival,in t...reduction in,relative risk of disease progression ... included prior Taxotere use,geographies, as well...causes of progression in the SPARC trial - radiolo...ssociated with a 36%,reduction in relative risk of...
...ndpoints, Wake After Sleep Onset and Total,Sleep T...y to,Persistent Sleep, were met at both doses - Ev...time, 10am EST) today , HAMBURG, Germany | OXFORD,...k Exchange: EVT) announced today positive top-line... EVT 201 in,patients with chronic primary insomnia...
Other Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4
Inquire
Adjustable speed vortex with inter-changeable heads, 110 V
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures.
...e Mo Bio Vortex Adapter in conjunction with the Vo...sing the Mo Bio Vortex Adapter is an inexpensive a...hines which offer the same technology. This parti...one time and will fit any Vortex Genie 2 with a 3 ...
Medicine Products: